(Q43181954)

English

A randomized phase I clinical and biologic study of two schedules of sorafenib in patients with myelodysplastic syndrome or acute myeloid leukemia: a NCIC (National Cancer Institute of Canada) Clinical Trials Group Study

scientific article published in February 2010

In more languages

default values for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

15 November 2017

A randomized phase I clinical and biologic study of two schedules of sorafenib in patients with myelodysplastic syndrome or acute myeloid leukemia: a NCIC (National Cancer Institute of Canada) Clinical Trials Group Study (English)

1 reference

Europe PubMed Central

PubMed publication ID

15 November 2017

phase I clinical trial

0 references

0 references

1 reference

based on heuristic

inferred from title

myelodysplastic syndrome

1 reference

based on heuristic

inferred from title

acute myeloid leukemia

1 reference

based on heuristic

inferred from title

object named as

David Hedley

2

0 references

Suzanne Kamel-Reid

object named as

Suzanne Kamel-Reid

3

0 references

author name string

Michael Crump

1

1 reference

Europe PubMed Central

PubMed publication ID

15 November 2017

Brian Leber

4

1 reference

Europe PubMed Central

PubMed publication ID

15 November 2017

Richard Wells

5

1 reference

Europe PubMed Central

PubMed publication ID

15 November 2017

Joseph Brandwein

6

1 reference

Europe PubMed Central

PubMed publication ID

15 November 2017

Rena Buckstein

7

1 reference

Europe PubMed Central

PubMed publication ID

15 November 2017

Janine Kassis

8

1 reference

Europe PubMed Central

PubMed publication ID

15 November 2017

Mark Minden

9

1 reference

Europe PubMed Central

PubMed publication ID

15 November 2017

John Matthews

10

1 reference

Europe PubMed Central

PubMed publication ID

15 November 2017

Sue Robinson

11

1 reference

Europe PubMed Central

PubMed publication ID

15 November 2017

Robert Turner

12

1 reference

Europe PubMed Central

PubMed publication ID

15 November 2017

Lynn McIntosh

13

1 reference

Europe PubMed Central

PubMed publication ID

15 November 2017

Elizabeth Eisenhauer

14

1 reference

Europe PubMed Central

PubMed publication ID

15 November 2017

Lesley Seymour

15

1 reference

Europe PubMed Central

PubMed publication ID

15 November 2017

publication date

1 February 2010

1 reference

Europe PubMed Central

PubMed publication ID

15 November 2017

Leukemia & Lymphoma

1 reference

Europe PubMed Central

PubMed publication ID

15 November 2017

51

1 reference

Europe PubMed Central

PubMed publication ID

15 November 2017

2

1 reference

Europe PubMed Central

PubMed publication ID

15 November 2017

252-260

1 reference

Europe PubMed Central

PubMed publication ID

15 November 2017

Drug therapy for acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.3109%2F10428190903585286

21 January 2018

Chemotherapy compared with autologous or allogeneic bone marrow transplantation in the management of acute myeloid leukemia in first remission

1 reference

https://api.crossref.org/works/10.3109%2F10428190903585286

21 January 2018

The value of the MDR1 reversal agent PSC-833 in addition to daunorubicin and cytarabine in the treatment of elderly patients with previously untreated acute myeloid leukemia (AML), in relation to MDR1 status at diagnosis

1 reference

https://api.crossref.org/works/10.3109%2F10428190903585286

21 January 2018

Use of glycosylated recombinant human G-CSF (lenograstim) during and/or after induction chemotherapy in patients 61 years of age and older with acute myeloid leukemia: final results of AML-13, a randomized phase-3 study

1 reference

https://api.crossref.org/works/10.3109%2F10428190903585286

21 January 2018

Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B.

1 reference

https://api.crossref.org/works/10.3109%2F10428190903585286

21 January 2018

The roles of FLT3 in hematopoiesis and leukemia

1 reference

https://api.crossref.org/works/10.3109%2F10428190903585286

21 January 2018

Activation of the RAS pathway is predictive for a chemosensitive phenotype of acute myelogenous leukemia blasts

1 reference

https://api.crossref.org/works/10.3109%2F10428190903585286

21 January 2018

Mechanisms of regulating the Raf kinase family

1 reference

https://api.crossref.org/works/10.3109%2F10428190903585286

21 January 2018

Raf: a strategic target for therapeutic development against cancer

1 reference

https://api.crossref.org/works/10.3109%2F10428190903585286

21 January 2018

Genetics of myeloid malignancies: pathogenetic and clinical implications

1 reference

https://api.crossref.org/works/10.3109%2F10428190903585286

21 January 2018

Clinical and biologic activity of the farnesyltransferase inhibitor R115777 in adults with refractory and relapsed acute leukemias: a phase 1 clinical-laboratory correlative trial

1 reference

https://api.crossref.org/works/10.3109%2F10428190903585286

21 January 2018

Dose-ranging pharmacodynamic study of tipifarnib (R115777) in patients with relapsed and refractory hematologic malignancies

1 reference

https://api.crossref.org/works/10.3109%2F10428190903585286

21 January 2018

BAY 43-9006: preclinical data

1 reference

https://api.crossref.org/works/10.3109%2F10428190903585286

21 January 2018

BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis

1 reference

https://api.crossref.org/works/10.3109%2F10428190903585286

21 January 2018

Mcl-1 as a buffer for proapoptotic Bcl-2 family members during TRAIL-induced apoptosis: a mechanistic basis for sorafenib (Bay 43-9006)-induced TRAIL sensitization.

1 reference

https://api.crossref.org/works/10.3109%2F10428190903585286

21 January 2018

Apoptosis induced by the kinase inhibitor BAY 43-9006 in human leukemia cells involves down-regulation of Mcl-1 through inhibition of translation

1 reference

https://api.crossref.org/works/10.3109%2F10428190903585286

21 January 2018

Report of the National Cancer Institute-sponsored workshop on definitions of diagnosis and response in acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.3109%2F10428190903585286

21 January 2018

Measurement of MAP kinase activation by flow cytometry using phospho-specific antibodies to MEK and ERK: potential for pharmacodynamic monitoring of signal transduction inhibitors.

1 reference

https://api.crossref.org/works/10.3109%2F10428190903585286

21 January 2018

Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461)

1 reference

https://api.crossref.org/works/10.3109%2F10428190903585286

21 January 2018

Antitumor activity of sorafenib in FLT3-driven leukemic cells

1 reference

https://api.crossref.org/works/10.3109%2F10428190903585286

21 January 2018

Phase I safety and pharmacokinetics of BAY 43-9006 administered for 21 days on/7 days off in patients with advanced, refractory solid tumours

1 reference

https://api.crossref.org/works/10.3109%2F10428190903585286

21 January 2018

Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors.

1 reference

https://api.crossref.org/works/10.3109%2F10428190903585286

21 January 2018

Mutant FLT3: a direct target of sorafenib in acute myelogenous leukemia

1 reference

https://api.crossref.org/works/10.3109%2F10428190903585286

21 January 2018

Internal and external autocrine VEGF/KDR loops regulate survival of subsets of acute leukemia through distinct signaling pathways

1 reference

https://api.crossref.org/works/10.3109%2F10428190903585286

21 January 2018

Common alterations in gene expression and increased proliferation in recurrent acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.3109%2F10428190903585286

21 January 2018

Identifiers

10.3109/10428190903585286

1 reference

Europe PubMed Central

PubMed publication ID

15 November 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

15 November 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q43181954&oldid=1983009605"